Morschhauser F, Fowler NH, Feugier P, et al. RELEVANCE: phase III efficacy and safety study of lenalidomide plus rituximab (R2) versus rituximab plus chemotherapy, followed by rituximab, in previously untreated follicular lymphoma. EHA 2018; abstract S154.
Fase I-onderzoek naar IL-10-producerende anti-CD19 CAR T-cellen bij r/r B-cel ALL
dec 2025 | Leukemie